Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 11
Submit an article Journal homepage
49
Views
3
CrossRef citations to date
0
Altmetric
Original Article

The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients

C. Crivera Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
,
D. C. Suh Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
,
E. S. Huang University of Chicago, Chicago, IL, USA
,
E. Cagliero Diabetes Unit, Massachusetts General Hospital and Harvard Medical School Boston, MA, USA
,
R. W. Grant General Medicine Division, Massachusetts General Hospital and Harvard Medical School Boston, MA, USA; Clinical Research Program, Massachusetts General Hospital and Harvard Medical School Boston, MA, USA
,
L. Vo Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
,
H. C. Shin Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
&
J. B. Meigs General Medicine Division, Massachusetts General Hospital and Harvard Medical School Boston, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School Boston, MA, USACorrespondence[email protected]
 show all
Pages 2301-2311 | Accepted 18 Aug 2006, Published online: 16 Oct 2006

References

  • American Diabetes Association: economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21: 296–309
  • American Diabetes Association: economic Costs of Diabetes in the U.S. in 2002. Diabetes Care 2003;26: 917–32
  • American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999;22 (Suppl 1):S32–41
  • Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001;111: 633–42
  • The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. JAMA 1998;280:1757–63
  • Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–44
  • The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction, for type 2 diabetes. JAMA 2002;287:2542–51
  • U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
  • Grant R, Cagliero E, Murphy-Sheehy P. Comparison of hyper-glycemia, hypertension and hypercholesteremia management in patients with type 2 diabetes. Am J Med 2002;112: 603–9
  • Bell DS. Current status of diabetes treatment. South Med J 2002;95:24–9
  • Leibovitz H. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001;30:909–33
  • American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 2004;27(Suppl 1):S1–134
  • American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care 1998;21(Suppl 1):S1–98
  • National Heart Lung and Blood Institute. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethseda, MD: National Institute of Health, 2001
  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure – the JNC 7 report. JAMA 2003;289:2560–72
  • American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25 (Suppl 1):S33–49
  • Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus (current management guidelines). Arch Intern Med 2003;163:33–40
  • American Society of Health-System Pharmacists. American hospital formulary service drug information. Bethesda, MD: American Society of Health-System Pharmacists, 2002
  • Facts and comparisons. Drug facts and comparisons. 58 edn. St. Louis: Facts and comparisons, 2003
  • Medical Economics Co. Red Book. Montvale: Medical Economics Co., 1998
  • Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton: Chapman and Hall/CRC, 1993
  • O’Hagan A, Stevens JW. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 2003;12:33–49
  • Rosner B. Fundamentals of Biostatistics. 5th edn. Belmont CA: Duxbury Press, 2000
  • SAS Institute Inc. The SAS system release 8.2. Cary, NC: SAS Institute
  • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–42
  • Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004;27:17–20
  • Casalino LP. Disease management and the organization of physician practice. JAMA 2005;293:485–8
  • Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93
  • Cohen FJ, Neslusan CA, Conklin JE, et al. Recent anti-hyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003;26: 1847–51
  • Nau DP, Garber MC, Herman WH. The intensification of drug therapy for diabetes and its complications: evidence from 2 HMOs. Am J Manag Care 2004;10: 118–23
  • Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26:1408–12

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.